Bladder Cancer

P=N/A, N=248, Recruiting, Umeå University | Trial completion date: Mar 2034 --> Jun 2034 | Trial primary completion date: Mar 2032 --> Jun 2032

Functional disruption of this axis suppressed primary tumor progression and lung metastasis in BMIBC models. Collectively, our findings define the KRT14-IGF2BP1 axis as a previously unrecognized, potentially targetable vulnerability in BMIBC, whose inhibition may limit aggressive disease progression and inform future therapeutic strategies.

P2, N=70, Active, not recruiting, University of Southern California | N=103 --> 70 | Trial completion date: Nov 2026 --> Dec 2030 | Trial primary completion date: Nov 2025 --> Dec 2027

Stage-tailored strategies are emerging, including risk assessment in NMIBC, refining adjuvant decisions in MIBC, and treatment monitoring in mUC. Integration of ctDNA-guided approaches should proceed alongside prospective validation to ensure safe and effective adoption.

P1, N=24, Not yet recruiting, Institut Cancerologie de l'Ouest | Trial completion date: Aug 2028 --> Jan 2030 | Initiation date: Feb 2026 --> Jan 2027 | Trial primary completion date: Aug 2027 --> Jan 2029

However, interpretation is constrained by small retrospective series, assay discordance, and the absence of standardized HER2 scoring criteria for UC. In the antibody-drug conjugate era, resolving these subtype-specific and methodological uncertainties is essential for refining patient selection and defining the clinical role of HER2-directed therapy across histologic subtypes and divergent histologist.

It also emphasizes that normal tumor marker levels do not exclude recurrence and that histopathological confirmation remains essential for accurate diagnosis. Recognition of unusual presentations in long-term survivors of germ cell tumors is important to facilitate timely diagnosis and appropriate management.

miR-33a-5p is a promising prognostic biomarker and potential therapeutic target for BLCA, with implications for risk stratification and targeted therapy in BLCA management.

Indeed, overexpression of SNAI2 enhanced the migratory capacity of bladder cancer cells via Transwell assay. Collectively, our findings demonstrate that EP300 promoted bladder cancer cell migration via up-regulating SNAI2, targeting EP300 could be a potential therapeutic strategy to inhibit the process of bladder cancer invasion.

ICAM5 serves as a novel prognostic biomarker and potential therapeutic target in bladder cancer, orchestrating EMT progression, reshaping the immune microenvironment, and driving resistance to immunotherapy.

Many tumors accumulated CNAs in bursts of evolution, suggesting that punctuated evolution is common in diverse cancer types. This study greatly improves our knowledge of intratumoral chromosome diversity across human cancers.

P2, N=33, Not yet recruiting, University of Washington | Initiation date: Jun 2026 --> Sep 2026